Muthuri, Stella G. and Venkatesan, Sudhir and Myles, Puja R. and Leonardi-Bee, Jo and Lim, Wei Shen and Al Mamun, Abdullah and Anovadiya, Ashish P and Araújo, Wildo N and Azziz‐Baumgartner, Eduardo and Báez, Clarisa and Bantar, Carlos and Barhoush, Mazen M and Bassetti, Matteo and Beovic, Bojana and Bingisser, Roland and Bonmarin, Isabelle and Borja‐Aburto, Victor H. and Cao, Bin and Carratala, Jordi and Cuezzo, María R. and Denholm, Justin T and Dominguez, Samuel R. and Duarte, Pericles A. D. and Dubnov‐Raz, Gal and Echavarria,, Marcela and Fanella, Sergio and Fraser, James and Gao, Zhancheng and Gérardin, Patrick and Giannella, Maddalena and Gubbels, Sophie and Herberg, Jethro and Higuera Iglesias, Anjarath L and Hoeger, Peter H and Hoffmann, Matthias and Hu, Xiaoyun and Islam, Quazi T and Jiménez, Mirela F. and Kandeel, Amr and Keijzers, Gerben and Khalili,, Hossein and Khandaker, Gulam and Knight, Marian and Kusznierz, Gabriela and Kuzman, Ilija and Kwan, Arthur M. C. and Lahlou Amine, Idriss and Langenegger, Eduard and Lankarani, Kamran B. and Leo, Yee‐Sin and Linko, Rita and Liu, Pei and Madanat, Faris and Manabe, Toshie and Mayo‐Montero, Elga and McGeer, Allison and Memish, Ziad A. and Metan, Gokhan and Mikić, Dragan and Mohn, Kristin G. I. and Moradi, Ahmadreza and Nymadawa, Pagbajabyn and Ozbay, Bulent and Ozkan, Mehpare and Parekh, Dhruv and Paul, Mical and Poeppl, Wolfgang and Polack, Fernando P and Rath, Barbara A. and Rodríguez, Alejandro H. and Siqueira, Marilda M. and Skręt‐Magierło, Joanna and Talarek, Ewa and Tang, Julian W. and Torres, Antoni and Törün, Selda H. and Tran, Dat and Uyeki, Timothy M. and van Zwol, Annelies and Vaudry, Wendy and Velyvyte, Daiva and Vidmar, Tjasa and Zarogoulidis, Paul and Nguyen-Van-Tam, Jonathan S.
Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09‐related pneumonia: an individual participant data meta‐analysis.
Influenza and Other Respiratory Viruses, 10
BACKGROUND: The impact of neuraminidase inhibitors (NAIs) on influenza‐related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection.
METHODS: A worldwide meta‐analysis of individual participant data from 20 634 hospitalised patients with laboratory‐confirmed A(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) ‘pandemic influenza’. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids.
RESULTS: Of 20 634 included participants, 5978 (29·0%) had IRP; conversely, 3349 (16·2%) had confirmed the absence of radiographic pneumonia (the comparator). Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj. OR 0·83 (95% CI 0·64–1·06; P = 0·136)]. Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj. OR = 0·72 (0·44–1·17; P = 0·180)] or likelihood of requiring ventilatory support [adj. OR = 1·17 (0·71–1·92; P = 0·537)], but early treatment versus later significantly reduced mortality [adj. OR = 0·70 (0·55–0·88; P = 0·003)] and likelihood of requiring ventilatory support [adj. OR = 0·68 (0·54–0·85; P = 0·001)].
CONCLUSIONS: Early NAI treatment of patients hospitalised with A(H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP. However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support.
||Hospitalisation, individual participant data meta-analyses,
influenza-related pneumonia, neuraminidase inhibitors.
||University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Epidemiology and Public Health
||26 Aug 2016 12:36
||17 Sep 2016 18:20
Actions (Archive Staff Only)